Dr. Helen Tayton-Martin joins our board, bringing decades of leadership in TCR-T cell therapy and biotech growth.

Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...

Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round.

Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence.

Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer

“I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini. “T cell therapies hold tremendous promises for tumor patients and the development of TCR T therapies is just gaining momentum. I am convinced that Pan Cancer T will play a pioneering role in this field, as the Company is working on the main challenges in the field: identifying novel tumor antigens and leveraging engineering technology to enhance the T cells´ durability.”

Expanded investor syndicate strengthens the company’s financial position and investor base